Respiratory research

Arsenic trioxide blocks a growth factor from turning lung support cells into scar-forming cells in lab tests and reduces lung scarring caused by bleomycin in animals

Updated

Abstract

Treatment with arsenic trioxide (ATO) at concentrations of 10-20nM significantly inhibits TGF-β1-induced fibrotic markers in lung fibroblasts.

  • ATO treatment reduces α-smooth muscle actin (α-SMA) and α-1 type I collagen expression in normal human lung fibroblasts.
  • The decrease in fibrotic markers is linked to the inhibition of Akt and Smad2/Smad3 phosphorylation.
  • ATO blocks TGF-β1-induced expression of H2O2 and NOX-4 mRNA.
  • In vivo, ATO administration (1 mg/kg) reduces bleomycin-induced collagen expression in mouse lungs.
  • PML nuclear bodies and protein expression are decreased with ATO treatment, indicating a potential pathway for its anti-fibrotic effects.

Simplified

Full Text

We can’t show the full text here under this license.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free